Based on the Arjo AB (publ) stock forecast from 0 analysts, the average analyst target price for Arjo AB (publ) is not available over the next 12 months. Arjo AB (publ)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arjo AB (publ) is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Arjo AB (publ)’s stock price was USD 3.89. Arjo AB (publ)’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.36% over the last year.
No recent analyst target price found for Arjo AB (publ)
No recent average analyst rating found for Arjo AB (publ)
Company Overview Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and safe working conditions for healthcare professionals in North America, Western Europe, and internationally. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, treatment and preventive injuries prevention, prevention of deep vein thrombosis and treatment of edema, leg ulcer treatment and prevention, and for obstetric and cardiac diagnostics. The company also provides dementia and bariatric room assessment solutions, as well as clinical consulting, maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden. Read Less
Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and safe working conditions for healthcare professionals in North America, Western Europe, and internationally. It offers products and solutions for patient handling, hygiene, disin...Read More
Frequently Asked Questions About Arjo AB (publ) (ARRJF) Stock
Stock Target Advisor's fundamental analysis for Arjo AB (publ)'s stock is Slightly Bearish.
ARRJF stock's dividend yield is 2.12%.
Our analysis grades ARRJF stock's dividend yield at F. This means that ARRJF stock's dividend yield is above 30% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this ARRJF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on ARRJF's stock to indicate what its average analyst target is.
ARRJF stock's Price/Earning ratio is 29.92.
Our analysis grades ARRJF stock's Price / Earning ratio at F. This means that ARRJF stock's Price/Earning ratio is above 78% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this ARRJF may be a overvalued for its sector.
The last closing price of ARRJF's stock was USD 3.89.
The most recent market capitalization for ARRJF is USD 0.99B.
Unfortunately we do not have enough analyst data on ARRJF's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARRJF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
